Free Trial

James Condulis Analyst Performance

Analyst at Stifel Nicolaus

James Condulis is a stock analyst at Stifel Nicolaus in the medical sector, covering 4 publicly traded companies. Over the past year, James Condulis has issued 6 stock ratings, including buy and hold recommendations. While full access to James Condulis' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights James Condulis' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
6 Last 0 Years
Buy Recommendations
83.33% 5 Buy Ratings
Companies Covered
4 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy83.3%5 ratings
Hold16.7%1 ratings
Sell0.0%0 ratings

Out of 6 total stock ratings issued by James Condulis at Stifel Nicolaus, the majority (83.3%) have been Buy recommendations, followed by 16.7% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
4 companies

James Condulis, an analyst at Stifel Nicolaus, currently covers 4 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
4 companies
100.0%

James Condulis of Stifel Nicolaus specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
2 companies
50.0%
MED - DRUGS
2 companies
50.0%

James Condulis' Ratings History at Stifel Nicolaus

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
9/2/2025Boost Price Target$47.85$96.00Buy
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
6/10/2025Initiated Coverage$20.16$44.00Buy
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3/28/2025Boost Price Target$70.64$108.00Buy
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3/5/2025Initiated Coverage$45.12$74.00Buy
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
1/22/2025Initiated Coverage$45.82$80.00Buy
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
1/22/2025Initiated Coverage$27.39$30.00Hold